Cargando…

Monoclonal Antibodies and Flaviviruses: a Possible Option?

M. P. Doyle, J. R. Genualdi, A. L. Bailey, N. Kose, et al. (mBio 13:e00512-22, 2022, https://doi.org/10.1128/mBio.00512-22), report on the cloning of a panel of fully human monoclonal antibodies (mAbs) directed against yellow fever virus (YFV). In particular, mAb YFV-136 is endowed with interesting...

Descripción completa

Detalles Bibliográficos
Autor principal: Mancini, Nicasio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239274/
https://www.ncbi.nlm.nih.gov/pubmed/35575500
http://dx.doi.org/10.1128/mbio.00824-22
_version_ 1784737264437297152
author Mancini, Nicasio
author_facet Mancini, Nicasio
author_sort Mancini, Nicasio
collection PubMed
description M. P. Doyle, J. R. Genualdi, A. L. Bailey, N. Kose, et al. (mBio 13:e00512-22, 2022, https://doi.org/10.1128/mBio.00512-22), report on the cloning of a panel of fully human monoclonal antibodies (mAbs) directed against yellow fever virus (YFV). In particular, mAb YFV-136 is endowed with interesting cross-YFV substrain-neutralizing features. The importance of YFV-136 and other mAbs with similar characteristics is related not necessarily only to their possible future use in the clinic but also to their role in a better understanding of the biology of YFV (as well as of other flaviviruses) for the development of effective therapeutic and prophylactic strategies. The emergence and reemergence of different flaviviruses worldwide in the last decades certainly make this a compelling clinical priority.
format Online
Article
Text
id pubmed-9239274
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-92392742022-06-29 Monoclonal Antibodies and Flaviviruses: a Possible Option? Mancini, Nicasio mBio Commentary M. P. Doyle, J. R. Genualdi, A. L. Bailey, N. Kose, et al. (mBio 13:e00512-22, 2022, https://doi.org/10.1128/mBio.00512-22), report on the cloning of a panel of fully human monoclonal antibodies (mAbs) directed against yellow fever virus (YFV). In particular, mAb YFV-136 is endowed with interesting cross-YFV substrain-neutralizing features. The importance of YFV-136 and other mAbs with similar characteristics is related not necessarily only to their possible future use in the clinic but also to their role in a better understanding of the biology of YFV (as well as of other flaviviruses) for the development of effective therapeutic and prophylactic strategies. The emergence and reemergence of different flaviviruses worldwide in the last decades certainly make this a compelling clinical priority. American Society for Microbiology 2022-05-16 /pmc/articles/PMC9239274/ /pubmed/35575500 http://dx.doi.org/10.1128/mbio.00824-22 Text en Copyright © 2022 Mancini. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Commentary
Mancini, Nicasio
Monoclonal Antibodies and Flaviviruses: a Possible Option?
title Monoclonal Antibodies and Flaviviruses: a Possible Option?
title_full Monoclonal Antibodies and Flaviviruses: a Possible Option?
title_fullStr Monoclonal Antibodies and Flaviviruses: a Possible Option?
title_full_unstemmed Monoclonal Antibodies and Flaviviruses: a Possible Option?
title_short Monoclonal Antibodies and Flaviviruses: a Possible Option?
title_sort monoclonal antibodies and flaviviruses: a possible option?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239274/
https://www.ncbi.nlm.nih.gov/pubmed/35575500
http://dx.doi.org/10.1128/mbio.00824-22
work_keys_str_mv AT mancininicasio monoclonalantibodiesandflavivirusesapossibleoption